Marker Therapeutics Inc (MRKR)

[microcapbiotech]

In 2019 they went from about $75 to about $5 and been between $5 and $15 up and down since then.

current SLS P3 trial:
Based on the above data and following review by the FDA, a pivotal Phase 3 clinical trial, the REGAL study, for AML patients in CR2 was commenced in January 2020. The REGAL study is a 1:1 randomized, open-label study comparing GPS monotherapy in the maintenance setting to investigators’ choice best available treatment in AML patients who have achieved hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allogeneic stem-cell transplantation. The primary endpoint is the overall survival (OS) from the time of study entry. Secondary endpoints include leukemia-free survival, antigen-specific T-cell immune response dynamics, measurable residual disease by multigene array, and assessments of AML clonal evolution and inflammasome molecular signatures in the tumor microenvironment in bone marrow biopsy samples. The study is expected to enroll approximately 116 patients across approximately 50 clinical sites in the United States and Europe.

Their P3 also has Fast Track and Orphan Drug.
https://clinicaltrials.gov/ct2/show/NCT04229979
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : April 2022

We ain't the only ones trying for cures.
We should find out soon how SLS did.